• In the past quarter, Opendoor Technologies Inc. reported second-quarter 2026 sales of US$883 million versus US$1,567 million a year earlier, with net loss widening to US$162 million and basic and diluted loss per share from continuing operations at US$0.17, while first-half 2026 sales reached US$1,603 million and net loss US$335 million.
• Despite these larger losses, management has guided to at least 20% year-over-year revenue growth for third-quarter 2026 and highlighted progress on AI-driven efficiencies, cost reductions, and the scaling of its integrated mortgage product as it works toward adjusted net income profitability on a 12-month go-forward basis by the end of 2026.
• Now we’ll assess how Opendoor’s confidence in achieving adjusted net income profitability by 2026 reshapes the existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

Opendoor Technologies Investment Narrative Recap

To own Opendoor, you have to believe that its data driven iBuying model, AI tools, and bundled mortgage offerings can eventually outweigh today’s heavy losses and balance sheet risk. The latest quarter’s deeper net loss and lower sales keep the most important near term catalyst firmly focused on Opendoor’s path to adjusted net income profitability, while also reinforcing that inventory exposure and debt levels remain the key risk rather than changing them in a material way.

The most relevant recent announcement is management’s guidance for at least 20% year over year revenue growth in third quarter 2026. That outlook sits directly against the weak second quarter numbers and puts more weight on Opendoor’s ability to convert AI efficiencies, mortgage cross sell, and platform expansion into healthier contribution margins, which many investors see as the clearest catalyst for any re rating of the stock over the next year.

Yet beneath this push toward profitability, investors should be aware that Opendoor’s significant inventory and debt exposure could still...

Opendoor Technologies' narrative projects $11.2 billion revenue and $633.0 million earnings by 2029. This requires 51.2% yearly revenue growth and about a $2.1 billion earnings increase from -$1.5 billion today.

Uncover how Opendoor Technologies' forecasts yield a $5.48 fair value, a 57% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming about 34% annual revenue growth and positive earnings by 2029, which is a far more upbeat story than the consensus view tied to gradual margin gains from AI and bundled services. After this earnings miss and cautious backdrop, you should expect these narratives to evolve and it is worth comparing how your own expectations stack up against such bullish forecasts.

Explore 11 other fair value estimates on Opendoor Technologies - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Opendoor Technologies research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Opendoor Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Opendoor Technologies' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 19 elite penny stocks that balance risk and reward.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.